trending Market Intelligence /marketintelligence/en/news-insights/trending/isFbj7O5u42INNNtBmUVZA2 content esgSubNav
In This List

Melinta Therapeutics interim CEO to assume permanent role

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Melinta Therapeutics interim CEO to assume permanent role

Melinta Therapeutics Inc. said John Johnson agreed to become the company's permanent CEO.

Johnson, who is a director of the New Haven, Conn.-based pharmaceutical company, has served as interim CEO since Oct. 22. He filled in for Dan Wechsler, who stepped down to pursue other opportunities.

The appointment is subject to the close of a previously announced commitment for a credit facility of up to $135 million from its largest shareholder, Vatera Healthcare Partners LLC.